WASHINGTON (Reuters) - Pfizer's Inlyta drug for patients with advanced kidney cancer won approval from U.S. regulators, boosting the company's efforts to offset plunging Lipitor sales. The Food and Drug Administration on Friday said the drug, known generically as axitinib, is effective at treating patients who do not respond to another drug for kidney cancer. Advanced kidney cancer starts in the ...